• Теги
    • избранные теги
    • Компании2786
      • Показать ещё
      • Показать ещё
      Международные организации51
      • Показать ещё
      Страны / Регионы425
      • Показать ещё
      • Показать ещё
      • Показать ещё
      • Показать ещё
Gilead Sciences
08 декабря, 16:02

Gilead поможет заработать на медпрепаратах для лечения ВИЧ

В пользу биотехов свидетельствуют следующие факторы: устойчивость к циклическим изменениям экономики, старение населения в развитых странах, все еще низкие процентные ставки в США (возможность привлечения дешевого долга для финансирования поглощений и прочих стратегических проектов).

Выбор редакции
30 ноября, 17:40

Is Gilead Sciences’ Stock in Good Health?

Gilead Sciences’ stock has had a rough year. But its fundamentals show a chance of recovery. Investors want to know... is it a good buy?

30 ноября, 03:39

10 US Companies Paying the Lowest (and Highest) Corporate Taxes

Ever wonder which companies are paying their fair share in corporate taxes, and which are paying little, if any? Here's the list.

25 ноября, 16:32

J&J (JNJ) Reportedly Approaches Actelion for Acquisition

Reportedly, Johnson & Johnson (JNJ) recently approached Swiss biotechnology company, Actelion Ltd. (ALIOF), with a potential takeover offer.

23 ноября, 16:24

Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease

Galapagos (GLPG) dosed the first patient in the phase III DIVERSITY study on filgotinib for the treatment of Crohn's disease.

Выбор редакции
23 ноября, 14:31

Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola

Focus is back on pipeline and regulatory updates with the end of the third quarter earnings season and elections.

Выбор редакции
21 ноября, 07:00

3 недооцененные акции, которые надо купить прямо сейчас

Уолл-стрит, судя по всему, не слишком привлекают бумаги Gilead Sciences, BorgWarner и Verizon Communications. А зря, ведь у них отличные перспективы. Рассказываем, почему.

17 ноября, 16:21

Gilead Reports Phase III Myelofibrosis Data on Momelotinib

Gilead Sciences (GILD) announced top-line data from two phase III studies on momelotinib in patients with myelofibrosis.

16 ноября, 16:12

Biotech Stock Roundup: Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved

The biotech sector responded favorably to Donald Trump's victory on hopes that there will be fewer drug pricing headwinds. Stocks like Vertex (VRTX) were up significantly.

16 ноября, 01:37

What A Trump Presidency Means For The Markets

U.S. President Elect Donald Trump came in to the Presidential race as an underdog, but came out on top. Hillary Clinton won the popular vote by a small margin, but Trump had a massive lead on Clinton in the electoral votes. In the end, Trump had 279 electoral votes versus Hillary Clinton's 218, and he only needed 270 to win. NY Times Presidential Election Results Now, when Trump was taking the lead, the overnight futures market went into panic mode, not knowing what's in store for the U.S. The S&P 500 and Dow Jones Industrial Average futures were down over 4 percent at one point overnight on November 8, 2016. The Nikkei 225 closed down over 5 percent and the Hang Seng Index closed down 2.16 percent. After the market opened, market participants were able to digest the U.S. Presidential election results and buyers stepped in. Despite the S&P 500 futures being down over 4 percent at one point while electoral votes were being tallied, the futures rebounded and the SPDR S&P 500 ETF (NYSEARCA: SPY) opened up down only 0.81 percent on November 9, 2016. By 10:35 AM ET, the SPDR S&P 500 ETF was down less than 0.50 percent. Additionally, the SPDR Dow Jones Industrial Average ETF (NYSEARCA: DIA) was down only 0.15 percent at 10:35 AM ET. The markets ended up higher by over 1 percent across the board after the election, a welcoming surprise for the economy. Despite Trump being largely unpopular with many Americans and the media, the markets are taking this news quite well. There are some sectors that should thrive under Trump's presidency, which include the biotechnology and pharmaceuticals industries, as well as the precious metals industry over the short term. However, Mexico-related companies and renewable energy companies should see weakness under Trump's presidency. Biotechnology and Pharmaceuticals Industry Prior to the election, Hillary Clinton was against price gouging in the biotech and pharma industry, which added a high degree of volatility to some big names in the industries. The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) tracks biotechnology and pharmaceutical equity securities listed on the NASDAQ, and it was down over 20 percent over the past year as of October 31, 2016. The news of Trump securing the U.S. Presidential candidacy was great for the biotech and pharma industry. If you recall, in 2015,Clinton tweeted about reforming the industry after Martin Shkreli raised the price of Daraprim from $13.50 per pill to $750 per pill. Additionally, she tweeted about Mylan raising the price of its two-pack EpiPen to over $600. Now, these companies don't have to worry as much about the price gouging scrutiny that would have stemmed from a Clinton presidency. The iShares Nasdaq Biotech ETF was up over 7 percent by 11:00 AM ET. The strong upside move was led by IBB's largest holdings, Celgene Corporation (NASDAQ: CELG), Biogen Inc. (NASDAQ: BIIB) and Gilead Science Inc. (NASDAQ: GILD). Celgene was up over 8 percent, Biogen over 6 percent and Gild nearly 6 percent at 11:00 AM ET. Some may call this a positive black swan event for the biotech and pharma industry. Precious Metals Precious metals are usually a good hedge for political risk. With Trump as the U.S. President elect, market participants may be looking to the precious metals industry to hedge some of the risk associated with his candidacy. The SPDR Gold Shares (NYSEARCA: GLD) opened up over 2 percent higher the day after the election, and investors could be piling into gold-related companies. Some ETFs and names to keep an eye on are: GLD, VanEck Vectors Gold Miners ETF (NYSEARCA: GDX) and VanEck Vectors Junior Gold Miners ETF (NYSEARCA: GDXJ). Additionally, you may want to keep Barrick Gold Corporation (NYSE: ABX), Newmont Mining Corporation (NYSE: NEM) and Newcrest Mining Limited. Mexico-Related Stocks Trump poses large risk to Mexico, after the comments he made leading up until the election. He's now the U.S. President elect, and Mexico-related ETFs and the Mexican peso will see weakness. USD/MXN spiked up over 13 percent at one point on November 9, 2016, but gave back some of its gains and remained up just over 8 percent by 11:00 AM ET. One of the largest ETFs tracking Mexican stocks, the iShares MSCI Mexico-Capped ETF (NYSEARCA: EWW) was down over 9 percent due to the news that Trump will be the next U.S. president. EWW aims to track MSCI Mexico IMI 25/50, an index composed of Mexican stocks. Trump's proposed policies on trade and immigration, in relation to Mexico, are severe risks to Mexico's economy, which could send EWW lower. By the end of trading, EWW was down over 8 percent. Energy Stocks Trump's view of global warming as a hoax will hit the renewable energy market and cause those stocks to fall. Saying global warming is a hoax is one of Trump's most senseless comments, and now that he took the win from Clinton, climate change could be put on the backburner of issues to be taken care of. With this thinking, money will flow out from renewable energy companies, a negative for the global climate. The Guggenheim Solar ETF (NYSEARCA: TAN) tracks the MAC Global Solar Energy Index and invests in stocks of large solar companies, such as SolarCity, First Solar, Canadian Solar and Trina Solar. Trump's presidency will reduce innovation in this industry, leading to negative effects on climate. The Guggenheim Solar ETF was down over 5 percent due to Trump's noxious view on global warming. Banking Industry The banking sector remained strong due to the implications of a Trump presidency. Banks surged higher after the results because Trump may reduce regulations in the industry. Trump's presidency is thought to be more business-friendly, which is a plus for the financial services industry. Banks have been largely vilified since the global financial crisis, and Trump's presidency could breathe new life into this industry as it hits multi-year highs. The iShares U.S. Financials ETF (NYSEARCA: IYF) is an exchange-traded fund that invests in some of the world's largest financial services companies, such as Berkshire Hathaway, JPMorgan Chase, Wells Fargo, Bank of America and Citigroup. The iShares U.S. Financials ETF gained over 2 percent due to Trump's business-friendly nature. The Bottom Line We still don't know what Trump will do until he does it. His comments have been filled with false promises, and he may not follow through with everything he said he will do. For now, Trump's candidacy is good news for some industries, but bad news for others. Specifically, the biotech and pharmaceuticals industries are poised to rebound now that there's no risk of Clinton changing regulations for the industry. Moreover, the precious metals industry could thrive depending on the political risk that Trump may add. Financial services companies benefit from a Trump candidacy since he could reduce regulations. However, Mexican stocks should see weakness, and there could be short opportunities in EWW and other Mexican-related stocks. Trump's presidency is bad for companies aiming to fight global warming, particularly solar ETFs. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

14 ноября, 17:26

Merck's Triple Combination HCV Therapy Positive in Phase III

Merck & Co., Inc. (MRK) announced positive data from three phase II trials evaluating its pipeline candidate, MK-3682, in combination with grazoprevir and ruzasvir1 for the treatment of chronic hepatitis C (HCV) infection.

Выбор редакции
14 ноября, 16:36

Gilead Sciences started at buy with $100 stock price target at Stifel Nicolaus

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

14 ноября, 16:04

Gilead (GILD) HBV Drug Vemlidy Gets Positive CHMP Opinion

The EMA's CHMP has rendered a positive opinion on Gilead's (GILD) MAA for its hepatitis B virus drug, Vemlidy, taking it a step closer to an EU approval.

11 ноября, 15:39

Drug Stocks' Q3 Earnings to Watch on Nov 14: ARGS, AST

What's in store for drug stocks Argos (ARGS) and Asterias (AST) when they report Q3 results on Nov 14?

10 ноября, 18:10

Stock Market News for November 10, 2016

Benchmarks finished higher on Wednesday as investors embraced the election of Republican Donald Trump as the president of the United States

10 ноября, 15:48

5 Top Biotech Stocks to Buy on Trump Victory

The case for buying biotech stocks has strengthened following the election of Donald Trump to the White House.

10 ноября, 15:14

Peek Into Drug Stocks' Q3 Earnings on Nov 11: XBIT & REPH

A couple of companies from the healthcare sector are expected to report their third-quarter results on Nov 11. Let's see how things are shaping up for their respective announcements.

09 ноября, 23:54

Отчет Gilead Sciences: что нового

Фармацевтическая компания Gilead Sciences Inc выпустила отчетность за 9 месяцев 2016 г. О чем говорят ее показатели деятельности?

09 ноября, 16:10

Drug Stocks Q3 Earnings Roster for Nov 10: AVXS, GBT & BPMC

Three more companies from the healthcare sector are set to report their third-quarter results on Nov 10.